Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: A feasiblity study

Shigeki Kusamura; F. Raspagliesi; D. Baratti; A. Gronchi; P. Casali; M. Deraco

Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: A feasiblity study

Shigeki Kusamura, F. Raspagliesi, D. Baratti, A. Gronchi, P. Casali, M. Deraco

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

The purpose of this study was to evaluate the feasibility and the outcome impact of cytoreductive surgery (CBS) followed by intraperitoneal hyperthermic perfusion (IPHP) in patients affected by uterine sarcoma (US). Ten US patients were treated with CRS+IPHP (closed technique, cisplatin+mitomycin C or cisplatin+doxorubicin). Median follow-up was 25 months (range: 2-61). Five patients received preoperative chemotherapy. Nine cases underwent optimal CRS. Five-year overall and progression-free survivals were 65% and 30%, respectively. There was no operative morbidity, nor mortality and nor toxicity. Sis patients presented disease progression. CBS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials.

Original language	English
Pages (from-to)	19-22
Number of pages	4
Journal	Journal of Chemotherapy
Volume	16
Issue number	SUPPL. 5
Publication status	Published - Nov 2004

Keywords

Peritonectomy and intraperitoneal hyperthermic perfusion
Uterine sarcoma

ASJC Scopus subject areas

Pharmacology (medical)
Microbiology (medical)

Access to Document

Fingerprint Dive into the research topics of 'Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: A feasiblity study'. Together they form a unique fingerprint.

Cite this

@article{bbde62738d5442ffb3e155caed4103ee,

title = "Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: A feasiblity study",

abstract = "The purpose of this study was to evaluate the feasibility and the outcome impact of cytoreductive surgery (CBS) followed by intraperitoneal hyperthermic perfusion (IPHP) in patients affected by uterine sarcoma (US). Ten US patients were treated with CRS+IPHP (closed technique, cisplatin+mitomycin C or cisplatin+doxorubicin). Median follow-up was 25 months (range: 2-61). Five patients received preoperative chemotherapy. Nine cases underwent optimal CRS. Five-year overall and progression-free survivals were 65% and 30%, respectively. There was no operative morbidity, nor mortality and nor toxicity. Sis patients presented disease progression. CBS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials.",

keywords = "Peritonectomy and intraperitoneal hyperthermic perfusion, Uterine sarcoma",

author = "Shigeki Kusamura and F. Raspagliesi and D. Baratti and A. Gronchi and P. Casali and M. Deraco",

year = "2004",

month = nov,

language = "English",

volume = "16",

pages = "19--22",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Maney Publishing",

number = "SUPPL. 5",

}

TY - JOUR

T1 - Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion

T2 - A feasiblity study

AU - Kusamura, Shigeki

AU - Raspagliesi, F.

AU - Baratti, D.

AU - Gronchi, A.

AU - Casali, P.

AU - Deraco, M.

PY - 2004/11

Y1 - 2004/11

N2 - The purpose of this study was to evaluate the feasibility and the outcome impact of cytoreductive surgery (CBS) followed by intraperitoneal hyperthermic perfusion (IPHP) in patients affected by uterine sarcoma (US). Ten US patients were treated with CRS+IPHP (closed technique, cisplatin+mitomycin C or cisplatin+doxorubicin). Median follow-up was 25 months (range: 2-61). Five patients received preoperative chemotherapy. Nine cases underwent optimal CRS. Five-year overall and progression-free survivals were 65% and 30%, respectively. There was no operative morbidity, nor mortality and nor toxicity. Sis patients presented disease progression. CBS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials.

AB - The purpose of this study was to evaluate the feasibility and the outcome impact of cytoreductive surgery (CBS) followed by intraperitoneal hyperthermic perfusion (IPHP) in patients affected by uterine sarcoma (US). Ten US patients were treated with CRS+IPHP (closed technique, cisplatin+mitomycin C or cisplatin+doxorubicin). Median follow-up was 25 months (range: 2-61). Five patients received preoperative chemotherapy. Nine cases underwent optimal CRS. Five-year overall and progression-free survivals were 65% and 30%, respectively. There was no operative morbidity, nor mortality and nor toxicity. Sis patients presented disease progression. CBS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials.

KW - Peritonectomy and intraperitoneal hyperthermic perfusion

KW - Uterine sarcoma

UR - http://www.scopus.com/inward/record.url?scp=11144235196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144235196&partnerID=8YFLogxK

M3 - Article

C2 - 15675470

AN - SCOPUS:11144235196

VL - 16

SP - 19

EP - 22

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 5

ER -